Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Liver

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5,504 result(s) found for: Liver. Displaying page 67 of 276.
    «« First « Previous 63  64  65  66  67  68  69  70  71  Next» Last»»
    EudraCT Number: 2012-004429-26 Sponsor Protocol Number: Atu027-I-02 Start Date*: 2013-02-25
    Sponsor Name:Silence Therapeutics GmbH
    Full Title: A Phase Ib/IIa study of combination therapy with Gemcitabine and Atu027 in subjects with locally advanced or metastatic pancreatic adenocarcinoma
    Medical condition: Locally advanced or metastatic pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10033600 Pancreatic adenocarcinoma non-resectable LLT
    17.1 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001515-12 Sponsor Protocol Number: 208127/120,/132,/133,/134,/137 Start Date*: 2015-06-24
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open, randomized, multicentre, multicountry study to compare the reactogenicity and evaluate the safety and immunogenicity of GSK Bio’s combined hepatitis A / hepatitis B vaccine (at l...
    Medical condition: Vaccination of healthy children from 1 to 11 years old against Hepatitis
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005579-10 Sponsor Protocol Number: A-93-52030-325 Start Date*: 2016-02-26
    Sponsor Name:IPSEN S.P.A.
    Full Title: EFFICACY AND SAFETY OF LANREOTIDE ATG 120 MG IN COMBINATION WITH TEMOZOLOMIDE IN SUBJECTS WITH PROGRESSIVE WELL DIFFERENTIATED THORACIC NEUROENDOCRINE TUMORS
    Medical condition: progressive well differentiated thoracic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007282 Carcinoid tumour pulmonary PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062476 Neuroendocrine tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10037342 Pulmonary carcinoid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068115 Metastatic carcinoid tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068118 Metastatic carcinoid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055108 Thymic cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002543-92 Sponsor Protocol Number: PO3523 Start Date*: 2007-01-31
    Sponsor Name:Schering-Plough Research Institute
    Full Title: A Safety and Efficacy Study of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Completed) NL (Completed) PT (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005646-39 Sponsor Protocol Number: BRTA-0100-016 Start Date*: 2006-01-12
    Sponsor Name:NERVIANO MEDICAL SCIENCES
    Full Title: Phase II exploratory study of brostallicin PNU-166196A in patients with ovarian cancer resistant/refractory to platinum based chemotherapy.
    Medical condition: Advanced/metastatic ovarian cancer resistant or refractory to platinum.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033128 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002924-16 Sponsor Protocol Number: FG-506-01-IT-02 Start Date*: 2004-10-22
    Sponsor Name:FUJISAWA
    Full Title: AN OPEN, MULTICENTRE, RANDOMISED PARALLEL GROUP CLINICAL STUDY TO COMPARE SAFETY AND EFFICACY OF TACROLIMUS FK506 WITH MONOCLONAL ANTI-IL2R ANTIBODIES DACLIZUMAB VS TACROLIMUS FK506 WITH STER...
    Medical condition: PREVENTION OF REJECTION OF SUBOPTIMAL LIVERS IN LIVER ALLOGRAFT RECIPIENTS. COMPARE SAFETY AND EFFICACY OF TACROLIMUS FK506 WITH MONOCLONAL ANTI-IL2R ANTIBODIES DACLIZUMAB VS TACROLIMUS FK506 ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019654 Hepatic and hepatobiliary disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017716-32 Sponsor Protocol Number: MEC09/02 Start Date*: 2010-12-30
    Sponsor Name:Academic Medical Center
    Full Title: A phase II, randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib and metformin in patients with locally advanced and metastastatic pancreatic c...
    Medical condition: locally advanced and metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    llt 10033604 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019505-42 Sponsor Protocol Number: LEG-SIL-LTX-03 Start Date*: 2010-05-26
    Sponsor Name:Rottapharm SpA
    Full Title: ESTUDIO ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LEGALON SIL EN EL TRATAMIENTO DE LA RECURRENCIA DE VHC EN EL INJERTO DE PACIENTES SOMETIDOS A UN T...
    Medical condition: Pacientes de 18-70 años afectados por VHC en espera de de un trasplante ortotópico de hígado / 18-70 years old patients affected by HCV awaiting orthotopic liver transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005831-13 Sponsor Protocol Number: CDKO-125a-005 Start Date*: 2009-02-17
    Sponsor Name:NERVIANO MEDICAL SCIENCES
    Full Title: Phase II study of PHA-848125AC as second line-treatment in pemetrexed pre-treated malignant pleural mesothelioma patients
    Medical condition: Malignant Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059518 Pleural mesothelioma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-006194-26 Sponsor Protocol Number: EC11-185 Start Date*: 2012-06-29
    Sponsor Name:JOSE LUIS MONTERO ALVAREZ
    Full Title: A phase IV, multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of Sorafenib in patients with hepatocellular carcinoma after radiological progression
    Medical condition: Advanced stage hepatocellular carcinoma (stage C of BCLC classification)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003306-45 Sponsor Protocol Number: CBKM120ZDE01T Start Date*: 2015-03-24
    Sponsor Name:Universitätsklinikum Tübingen
    Full Title: An open-label, uncontrolled, single arm phase II trial of BKM120 (Buparlisib) in patients with metastatic melanoma with brain metastases not eligible for surgery or radiosurgery
    Medical condition: metastatic melanoma with brain metastases
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003370-33 Sponsor Protocol Number: M15-684 Start Date*: 2016-01-05
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: An Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Adults With Genotype 1b Hepatitis C Virus (HCV) Without Cir...
    Medical condition: Hepatitis C Infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005675-16 Sponsor Protocol Number: FBS0701-CTP-16 Start Date*: 2012-05-15
    Sponsor Name:FERROKIN BIOSCIENCES INC.
    Full Title: A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two FBS0701 Doses in the Treatment of Chronic Iron Overlo...
    Medical condition: Patients with transfusional iron overload, with the following primary diagnosis:hereditary anemia (such as sickle cell disease),β-thalassemia and Diamond Blackfan anemia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024068-16 Sponsor Protocol Number: LAL-CL01 Start Date*: 2011-03-08
    Sponsor Name:Synageva Biopharma Corp.
    Full Title: An open label multicenter study to evaluate the safety, tolerability and pharmacokinetics of SBC-102 in adult patients with liver dysfunction due to lysosomal acid lipase deficiency.
    Medical condition: Lysosomal Acid Lipase (LAL) Deficiency is a rare autosomal recessive lipid storage disorder that is caused by deficient activity or absence, of the lysosomal enzyme, LAL. It is an extremely rare di...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    14.0 10027433 - Metabolism and nutrition disorders 10021605 Inborn errors of metabolism HLGT
    14.0 10010331 - Congenital, familial and genetic disorders 10024579 Lysosomal storage disorders HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-001531-20 Sponsor Protocol Number: 103860/280,101695,101696,/697,/698 Start Date*: 2015-06-26
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, single-blinded, randomized, multicentric study to compare the immunogenicity of GlaxoSmithKline Biologicals' thiomersal-free 2-dose Engerix™-B (20 mcg) and 3-dose preservative-free Eng...
    Medical condition: Hepatitis B vaccination of healthy adolescents.
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-003817-32 Sponsor Protocol Number: LOLA-Merz:WMDHP39937 Start Date*: 2013-01-08
    Sponsor Name:Imperial College London
    Full Title: Brain muscle axis during treatment of hepatic encephalopathy with L-ornithine L-aspartate
    Medical condition: Hepatic Encephalopathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10019660 Hepatic encephalopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019885-10 Sponsor Protocol Number: Dermatux Start Date*: 2011-01-05
    Sponsor Name:Universitätsmedizin Mainz (vertreten durch den wissenschaftlichen Vorstand)
    Full Title: Non-randomized phase-IV-study to investigate the efficacy of FOLFIRI in combination with cetuximab in the first-line treatment of metastatic colorectal cancer inculding a regular dermal prophylaxis...
    Medical condition: metastatic colorectal cancer (mCRC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004370-14 Sponsor Protocol Number: 20150930 Start Date*: 2016-07-07
    Sponsor Name:University Medical Center Groningen
    Full Title: 89Zr-AMG211 PET imaging in patients with relapsed/refractory gastrointestinal adenocarcinoma before and during treatment with AMG 211
    Medical condition: Relapsed/refractory gastrointestinal adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002192-18 Sponsor Protocol Number: TRIO020 Start Date*: 2013-10-17
    Sponsor Name:Translational Research In Oncology
    Full Title: A randomized open-label Phase II study of letrozole plus afatinib (BIBW2992) versus letrozole alone in first-line treatment of advanced ER+, HER2- postmenopausal breast cancer with low ER expression
    Medical condition: Advanced ER+, HER2- postmenopausal breast cancer with low ER expression
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-005106-79 Sponsor Protocol Number: ST1481-DM02-008 Start Date*: 2005-02-01
    Sponsor Name:Sigma Tau industrie Farmaceutiche Riunite Spa
    Full Title: Phase II study of gimatecan (ST 1481) as salvage treatment in patients with advanced breast cancer after anthracycline /taxanes-based chemotherapy regimen
    Medical condition: advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    10006285 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 63  64  65  66  67  68  69  70  71  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Aug 07 13:24:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA